- Rezolute (NASDAQ:RZLT) rose 6% after it announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ersodetug for the treatment of hypoglycemia due to congenital HI.
- The Breakthrough Therapy Designation is based primarily on results from the Phase 2b study of ersodetug in participants with congenital HI, which safely demonstrated significant improvements in hypoglycemia of 75% or better, with no clinically significant hyperglycemia.
- Source: Press Release
Rezolute receives breakthrough therapy designation for treatment of hypoglycemia
By Press Room
